Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Jun 02, 2019 11:01am
109 Views
Post# 29792198

RE:RE:RE:RE:RE:You are amazing Claridge

RE:RE:RE:RE:RE:You are amazing ClaridgeHempdoc ... Thanks for posting the Neuro-Oncology Advances journal paper on our Rutherrin in the GBM indication.

It's another hint that the GBM indication is around the corner.  Dr. Lilge once mentioned that when it's innovations in unchartered territories, FDA/HC regulatories bodies ask them to publish in peer-reviewed journals.  If you noticed, this article is "open", so it can receive comments by neuro-oncologists.



__________

Hempdoc - (6/1/2019 8:10:07 PM) 

RE:RE:RE:RE:You are amazing Claridge

Having such invaluable technology/IP makes any near-term valuation of this company impossible, & the reason I hope TLT holds off on any JV/takeover as long as they possibly can.  Not only will their laser/dosimetry evolve, so will their development of new organometallic complexes.  Fortunately for us, Rutherrin is a great start & has few serious rivals.  IMO, it is the perfect Trojan Horse, a form of chemical subterfuge that gifts cancer its main staple for growth (iron) in a well-veiled poison (Rutherrin).  Then shine a little light & voila...

Claridge was correct in saying that we are very privileged (& even blessed) to have been presented with such an opportunity.  It is a rare & precious occasion to be able to invest in something that can potentially save millions of lives while also affording the “real” potential to make a personal fortune along the way...this is certainly no Trojan Horse for shareholders.  Good luck..

This was recently published in Neuro-Oncology Advances journal:

https://academic.oup.com/noa/advance-article/doi/10.1093/noajnl/vdz006/5499230?searchresult=1
Bullboard Posts